Cargando…
Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study
BACKGROUND AND AIMS: The reference interval (RI) for a tumor marker may vary between populations, detection systems, and the methods used to obtain their values. The aims of this study were to establish age‐ and sex‐specific RIs for the following nine common tumor markers and to validate the establi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919475/ https://www.ncbi.nlm.nih.gov/pubmed/36789402 http://dx.doi.org/10.1002/hsr2.1107 |
_version_ | 1784886834170429440 |
---|---|
author | Nah, Eun‐Hee Cho, Seon Park, Hyeran Kim, Suyoung Kwon, Eunjoo Cho, Han‐Ik |
author_facet | Nah, Eun‐Hee Cho, Seon Park, Hyeran Kim, Suyoung Kwon, Eunjoo Cho, Han‐Ik |
author_sort | Nah, Eun‐Hee |
collection | PubMed |
description | BACKGROUND AND AIMS: The reference interval (RI) for a tumor marker may vary between populations, detection systems, and the methods used to obtain their values. The aims of this study were to establish age‐ and sex‐specific RIs for the following nine common tumor markers and to validate the established RIs in Korean adults: alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen (CA) 19‐9, CA15‐3, CA125, Human epididymis protein 4 (HE4), total prostate specific antigen, cytokeratin fragment (Cyfra) 21‐1, and progastrin‐releasing peptide (ProGRP). METHODS: This cross‐sectional study consecutively selected 214,159 individuals (aged 18–98 years) who underwent health checkups at 16 health‐promotion centers in 13 Korean cities. Finally, 62,752 examinees were used to establish the RIs after removing outliers. RIs were established using an indirect method according to the CLSI EP28‐A3C guideline. The established RIs were validated by calculating the proportion of individuals outside each RI. RESULTS: Sex‐related differences were observed for AFP, CEA, CA19‐9, Cyfra 21‐1, and ProGRP (p < 0.05): AFP, CEA and Cyfra 21‐1 were higher in males, and CA19‐9 and proGRP were higher in females. Most of the tumor markers except CA15‐3 and CA125 increased with age: CA125 decreased at ≥50 years of age (p < 0.05), while CA15‐3 did not vary with age. Less than 5% of subjects were outside all RIs (the 2.5th and 97.5th percentiles) established in the present study. Meanwhile, less than 3% of the healthy reference subjects fell outside the current and manufacturers' RIs of all tumor markers except Cyfra 21‐1. CONCLUSION: This study has determined age‐ and sex‐specific RIs for nine common tumor markers in the healthy Korean population, which could be useful for clinicians making clinical decisions and assessments. |
format | Online Article Text |
id | pubmed-9919475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99194752023-02-13 Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study Nah, Eun‐Hee Cho, Seon Park, Hyeran Kim, Suyoung Kwon, Eunjoo Cho, Han‐Ik Health Sci Rep Original Research BACKGROUND AND AIMS: The reference interval (RI) for a tumor marker may vary between populations, detection systems, and the methods used to obtain their values. The aims of this study were to establish age‐ and sex‐specific RIs for the following nine common tumor markers and to validate the established RIs in Korean adults: alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen (CA) 19‐9, CA15‐3, CA125, Human epididymis protein 4 (HE4), total prostate specific antigen, cytokeratin fragment (Cyfra) 21‐1, and progastrin‐releasing peptide (ProGRP). METHODS: This cross‐sectional study consecutively selected 214,159 individuals (aged 18–98 years) who underwent health checkups at 16 health‐promotion centers in 13 Korean cities. Finally, 62,752 examinees were used to establish the RIs after removing outliers. RIs were established using an indirect method according to the CLSI EP28‐A3C guideline. The established RIs were validated by calculating the proportion of individuals outside each RI. RESULTS: Sex‐related differences were observed for AFP, CEA, CA19‐9, Cyfra 21‐1, and ProGRP (p < 0.05): AFP, CEA and Cyfra 21‐1 were higher in males, and CA19‐9 and proGRP were higher in females. Most of the tumor markers except CA15‐3 and CA125 increased with age: CA125 decreased at ≥50 years of age (p < 0.05), while CA15‐3 did not vary with age. Less than 5% of subjects were outside all RIs (the 2.5th and 97.5th percentiles) established in the present study. Meanwhile, less than 3% of the healthy reference subjects fell outside the current and manufacturers' RIs of all tumor markers except Cyfra 21‐1. CONCLUSION: This study has determined age‐ and sex‐specific RIs for nine common tumor markers in the healthy Korean population, which could be useful for clinicians making clinical decisions and assessments. John Wiley and Sons Inc. 2023-02-11 /pmc/articles/PMC9919475/ /pubmed/36789402 http://dx.doi.org/10.1002/hsr2.1107 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Nah, Eun‐Hee Cho, Seon Park, Hyeran Kim, Suyoung Kwon, Eunjoo Cho, Han‐Ik Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study |
title | Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study |
title_full | Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study |
title_fullStr | Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study |
title_full_unstemmed | Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study |
title_short | Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19‐9, CA15‐3, CA125, PSA, HE4, Cyfra 21‐1, and ProGRP) in primary care centers in Korea: A cross‐sectional retrospective study |
title_sort | establishment and validation of reference intervals for tumor markers (afp, cea, ca19‐9, ca15‐3, ca125, psa, he4, cyfra 21‐1, and progrp) in primary care centers in korea: a cross‐sectional retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919475/ https://www.ncbi.nlm.nih.gov/pubmed/36789402 http://dx.doi.org/10.1002/hsr2.1107 |
work_keys_str_mv | AT naheunhee establishmentandvalidationofreferenceintervalsfortumormarkersafpceaca199ca153ca125psahe4cyfra211andprogrpinprimarycarecentersinkoreaacrosssectionalretrospectivestudy AT choseon establishmentandvalidationofreferenceintervalsfortumormarkersafpceaca199ca153ca125psahe4cyfra211andprogrpinprimarycarecentersinkoreaacrosssectionalretrospectivestudy AT parkhyeran establishmentandvalidationofreferenceintervalsfortumormarkersafpceaca199ca153ca125psahe4cyfra211andprogrpinprimarycarecentersinkoreaacrosssectionalretrospectivestudy AT kimsuyoung establishmentandvalidationofreferenceintervalsfortumormarkersafpceaca199ca153ca125psahe4cyfra211andprogrpinprimarycarecentersinkoreaacrosssectionalretrospectivestudy AT kwoneunjoo establishmentandvalidationofreferenceintervalsfortumormarkersafpceaca199ca153ca125psahe4cyfra211andprogrpinprimarycarecentersinkoreaacrosssectionalretrospectivestudy AT chohanik establishmentandvalidationofreferenceintervalsfortumormarkersafpceaca199ca153ca125psahe4cyfra211andprogrpinprimarycarecentersinkoreaacrosssectionalretrospectivestudy |